2024
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
18/07/2024Congratulations to the Co-Founder and Chief Scientific Officer, Gloria Gonzalez-Aseguinolaza who has been honored with the prestigious Rosalind Franklin Society (RFS) Special Award in Science for her remarkable contributions and dedication to advancing scientific knowledge.
Read More
Integra Therapeutics receive up to €10.5 million from European Commission for its FiCAT advanced therapies platform
18/07/2024Integra Therapeutics, backed by Columbus and Invivo, receive up to €10.5 million from European Commission for its FiCAT advanced therapies platform.
Read More
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain
11/06/2024Minoryx announces that results from a compassionate use study of leriglitazone for treatment of progressive cerebral adrenoleukodystrophy (cALD) in adult male patients was published in the peer-reviewed journal Brain.
Read More
Syngoi Technologies Expands Synthetic DNA Manufacturing Capacity Following Series B Investment Led by Columbus Venture Partners
10/06/2024We’re thrilled to announce that Syngoi Technologies has significantly expanded its synthetic DNA manufacturing capacity, thanks to a successful Series B investment round led by COLUMBUS VP. Asahi Kasei Medical has joined Columbus VP in this strategic investment.
Read More
Highlight Therapeutics announces first patient dosed in Phase lla study in basal cell carcinoma
28/05/2024A clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the enrollment of the first patient in SPOTLIGHT-204, a phase 2 clinical evaluation of BO-112, Highlight’s lead asset, in patients with basal cell carcinoma (BCC).
Read MoreColumbus VP closes its fourth 150 million fund aimed at developing biotech start-ups
15/05/2024Columbus VP closes its fourth 150 million fund aimed at developing biotech start-ups The fund has managed more than 400 million... Read More
From seven to 435 workers in six years: the miracle of the virus cure factory
11/04/2024An advanced therapies company against lethal diseases, Viralgen, has propelled San Sebastian to become the city with the highest R&D weight…
Read MoreMultiverse raises $27M for quantum software targeting LLM leviathans
13/03/2024We’re still years away from seeing physical quantum computers break into the market with any scale and reliability, but don’t give…
Read More
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIaArthemiRTM Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
28/02/2024ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced that the U.S….
Read MoreCurve Therapeutics raises £40.5 million
27/02/2024Curve Therapeutics has raised £40.5 million to turbocharge its discovery platform and advance its breakthrough pipeline. The Series A financing was led by Pfizer Ventures, with new investors Columbus Venture Partners and British Patient Capital joining founding investor Advent Life Sciences and seed investor Epidarex Capital.
Read More